Methyl 3-{[(2,5-difluorophenyl)sulfonyl]amino}benzoate | 902717-20-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methyl 3-{[(2,5-difluorophenyl)sulfonyl]amino}benzoate
• 英文别名: methyl 3-[(2,5-difluorophenyl)sulfonylamino]benzoate
• CAS: 902717-20-8
• 化学式: C₁₄H₁₁F₂NO₄S
• 分子量: 327.308
• InChiKey: LXLHDDGWBDMKQV-UHFFFAOYSA-N

物化性质

• 沸点：
  451.9±55.0 °C(Predicted)
• 密度：
  1.455±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Methyl 3-{[(2,5-difluorophenyl)sulfonyl]amino}benzoate 在 N-溴代丁二酰亚胺(NBS) 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 N,N-二甲基乙酰胺 为溶剂， 反应 1.25h， 生成
  参考文献：
  名称：

  Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors

  摘要：

  Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-Raf(v600E) mutated enzyme has been observed in a number of human tumors, including melanomas. Herein we report the discovery and biological evaluation of GSK2118436, a selective inhibitor of Raf kinases with potent in vitro activity in oncogenic B-Raf-driven melanoma and colorectal carcinoma cells and robust in vivo antitumor and pharmacodynamic activity in mouse models of B-Raf(v600E) human melanoma. GSK2118436 was identified as a development candidate, and early clinical results have shown significant activity in patients with B-Raf mutant melanoma.

  DOI：

  10.1021/ml4000063
• 作为产物：
  描述：

  间氨基苯甲酸 在 吡啶 、 硫酸 作用下， 以 二氯甲烷 为溶剂， 生成 Methyl 3-{[(2,5-difluorophenyl)sulfonyl]amino}benzoate
  参考文献：
  名称：

  Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors

  摘要：

  Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-Raf(v600E) mutated enzyme has been observed in a number of human tumors, including melanomas. Herein we report the discovery and biological evaluation of GSK2118436, a selective inhibitor of Raf kinases with potent in vitro activity in oncogenic B-Raf-driven melanoma and colorectal carcinoma cells and robust in vivo antitumor and pharmacodynamic activity in mouse models of B-Raf(v600E) human melanoma. GSK2118436 was identified as a development candidate, and early clinical results have shown significant activity in patients with B-Raf mutant melanoma.

  DOI：

  10.1021/ml4000063

文献信息

• Benzene Sulfonamide Thiazole and Oxazole Compounds
  申请人：Adams Jerry Leroy

  公开号：US20090298815A1

  公开（公告）日：2009-12-03

  The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供了噻唑磺胺和噁唑磺胺化合物，含有这些化合物的组合物，以及用作药物制剂的制备方法和使用方法。
• Benzene Sulfonamide Thiazole And Oxazole Compounds
  申请人：Adjabeng George

  公开号：US20110172215A1

  公开（公告）日：2011-07-14

  The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供了噻唑磺酰胺和噁唑磺酰胺化合物，含有这些化合物的组合物，以及制备这些化合物的过程和将其用作药物的方法。
• Benzene sulfonamide thiazole and oxazole compounds
  申请人：Glaxo Smith Kline LLC

  公开号：US07994185B2

  公开（公告）日：2011-08-09

  The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供了噻唑磺酰胺和噁唑磺酰胺化合物，包含它们的组合物，以及制备这些化合物的方法和将其用作药物的方法。
• Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup
  作者：John C. Stellwagen、George M. Adjabeng、Marc R. Arnone、Scott H. Dickerson、Chao Han、Keith R. Hornberger、Alastair J. King、Robert A. Mook、Kimberly G. Petrov、Tara R. Rheault、Cynthia M. Rominger、Olivia W. Rossanese、Kimberly N. Smitheman、Alex G. Waterson、David E. Uehling

  DOI：10.1016/j.bmcl.2011.06.021

  日期：2011.8

  A potent series of inhibitors against the B-RafV600E kinase have been developed that show excellent activity in cellular assays and good oral bioavailability in rats. The key structural features of the series are an arylsulfonamide headgroup, a thiazole core, and a fluorine ortho to the sulfonamide nitrogen. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.
• BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS
  申请人：GlaxoSmithKline LLC

  公开号：EP2282636A2

  公开（公告）日：2011-02-16